The move to OTCQB will trigger forced selling by institutional investors who cannot hold OTC stocks. Expect significant price decline on May 5. The appeal hearing offers a slim chance of reinstatement, but the trading suspension is immediate and not stayed. Traders should avoid holding through the transition.
Price Chart
Executive Summary
Sangamo Therapeutics received a delisting notice from Nasdaq on April 28, 2026, due to its stock price remaining below $1.00 for over a year. Trading will be suspended on May 5, 2026, and the company will move to the OTCQB Venture Market under the same ticker SGMO. The company plans to appeal the delisting, but the trading suspension will not be stayed pending the hearing.
Key Facts
- Nasdaq notified Sangamo on April 28, 2026, that its common stock will be delisted due to failure to maintain the minimum $1.00 bid price for continued listing.
- Trading on Nasdaq will be suspended at the open on May 5, 2026.
- Sangamo has received approval to quote its common stock on the OTCQB Venture Market, with trading expected to commence on May 5, 2026, under the symbol SGMO.
- The company plans to request a hearing before a Nasdaq Hearings Panel to appeal the delisting determination, but the trading suspension will not be stayed.
- The company had previously received a deficiency notice on April 30, 2025, and was granted an additional 180-day compliance period until April 27, 2026, which it failed to meet.
Financial Impact
Delisting from Nasdaq to OTCQB will severely reduce liquidity and institutional ownership, likely causing significant downward pressure on the stock price. Market cap is $83M.
Risk Factors
- Immediate trading suspension on Nasdaq on May 5, 2026, leading to a liquidity crunch.
- Loss of institutional investors and analyst coverage due to OTCQB listing.
- Potential further decline in stock price as the company faces ongoing compliance and funding challenges.
- Appeal process may not result in reinstatement, and the company may remain on OTCQB indefinitely.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-028128 |
| Document: 0001628280-26-028128-index-headers.html | 0001628280-26-028128 |
| Document: 0001628280-26-028128-index.html | 0001628280-26-028128 |
| Document: 0001628280-26-028128.txt | 0001628280-26-028128 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jul 1, 2026 13w ago | 8-K | $0.0740 awaiting T+20 | awaiting T+20 | — | — |
Apr 29, 2026 22w ago | 8-K | $0.1300 $0.2000 | ▼ −53.85% | ▼ −48.39% | — |
Apr 21, 2026 23w ago | Insider Cluster | $0.2600 $0.1300 | ▼ −50.00% | ▼ −54.91% | — |
Mar 30, 2026 26w ago | Press Release | $0.2500 $0.1387 | ▼ −44.52% | ▼ −53.94% | — |
Mar 19, 2026 28w ago | Press Release | $0.3300 $0.2700 | ▼ −18.18% | ▼ −27.50% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access